Featured Posts
Blog
Free the Economy podcast: Drug costs and benefits with Sally Pipes
In this week’s episode we cover reforms to the Endangered Species Act, attacks on US tech firms, nuclear power innovation,…
National Review
Telehealth Is Less Promising Than It First Seemed
A key issue facing Congress in its postelection, “lame duck” session is whether to extend regulatory flexibilities expiring at year end that make telehealth services more…
City Journal
The FTC Jettisons Economics—and Law
The Federal Trade Commission is stepping up its pursuit of its new favorite bogeyman: Pharmacy Benefit Managers. Two months ago, the FTC issued an …
Search Posts
Study
The True State Of The Planet
The True State of the Planet: Ten of the World’s Premier Environmental Researchers in a Major Challenge to the Environmental Movement Date: 1995 Edited…
Op-Eds
Deadly Overcaution: FDA’s Drug Approval Process
Full article available in PDF When the federal Food and Drug Administration announces its approval of an important new drug, the…
Op-Eds
Biotechnology Flirts with the Regulators
Biotechnology, like other unfamiliar high tech industries, offers great hopes but arouses even greater fears. Politicians, the record proves, are far more likely to respond to…